Handok

WELT is a stylish smart belt designed for both fashion and healthcare purposes. It tracks waist size, steps taken, sitting time, and overeating habits, providing personalized health insights via Bluetooth to its accompanying app.

SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

WELT is a stylish smart belt designed for both fashion and healthcare purposes. It tracks waist size, steps taken, sitting time, and overeating habits, providing personalized health insights via Bluetooth to its accompanying app.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Rezolute Inc., established in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company's primary product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b trials for treating congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical stages for diabetic macular edema treatment. The company aims to improve existing standards of care by applying proprietary formulation and manufacturing capabilities to known molecules.